PIA
CLVS

Piedmont Investment Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Piedmont Investment Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-827
Closed -$38K – 2527
2018
Q2 		$38K Buy
+827
New +$40.2K ﹤0.01% 1392

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Piedmont Investment Advisors's CLVS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 827 shares — an estimated $38K sold.

Piedmont Investment Advisors first reported a position in CLVS in Q2 2018 and held it in 1 quarter. The position peaked at $38K in Q2 2018. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 827 Clovis Oncology, Inc. shares in Q3 2018, an estimated $38K.
  • Piedmont Investment Advisors first reported a position in Clovis Oncology, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Clovis Oncology, Inc. position peaked at $38K in Q2 2018.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.